title: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy and side effects of radioimmunotherapies with Zevalin(®) (RIT-Z) in Japanese patients with low-grade B-cell non-Hodgkin lymphoma (NHL).
  
  
  METHODS
  Sixty-two patients with NHL were enrolled. Based on histology, 49 of the patients had follicular lymphoma and 23 had other lesions. The response was assessed at 8-12 weeks after RIT-Z injection with PET/CT.
  
  
  RESULTS
  The overall response rate was 85 %. Thirty-seven (60 %) patients achieved complete remission, 16 (26 %) had partial remission, 4 (6 %) had stable disease, and 5 (8 %) had progressive disease. There was a significant correlation between the response to RIT-Z, frequency of chemotherapy, and history of prior treatment with fludarabine. There was no significant difference in efficacy according to lymphoma type, years since last chemotherapy, patient age, or disease stage at RIT-Z. Thrombocytopenia of grade 4 was significantly correlated with disease stage at RIT-Z and history of prior treatment with fludarabine. There was also no significant correlation between hematotoxicity and lymphoma type, frequency of chemotherapy, years since last chemotherapy, patient age, or history of bone marrow transplant. Anemia was significantly correlated with frequency of chemotherapy, history of bone marrow transplant, and history of prior treatment with fludarabine.
  
  
  CONCLUSIONS
  The response rate was high, and we were able to decrease the hematologic side effects by using RIT-Z earlier.
authors: Division of Radiology, Koga Hospital 21, 3-3-8 Miyanojin, Kurume 839-0801, Japan. nanchan-kyu@umin.ac.jp
authors: Makoto
authors: M
authors: Nakagawa
authors: Naokuni
authors: N
authors: Uike
authors: Ilseung
authors: I
authors: Choi
authors: Toshinobu
authors: T
authors: Hayashi
authors: Satoru
authors: S
authors: Uehara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D007564:Japan; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods; D049268:Positron-Emission Tomography; D016499:Radioimmunotherapy / Q000379:methods; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; C422802:ibritumomab tiuxetan